ATI RN
ATI Pharmacology Proctored Exam
1. A client is withdrawing from alcohol and has a new prescription for Propranolol. Which of the following information should be included in the teaching?
- A. Increases the risk for seizure activity.
- B. Provides a form of aversion therapy.
- C. Decreases cravings.
- D. Results in mild hypertension.
Correct answer: C
Rationale: The correct answer is C: 'Decreases cravings.' Propranolol is commonly used as an adjunct medication during alcohol withdrawal to help reduce cravings for alcohol. It does not increase the risk for seizure activity, provide aversion therapy, or result in mild hypertension. By decreasing cravings, Propranolol can support the client in managing alcohol withdrawal symptoms and promoting abstinence. Therefore, it is important to educate the client on how Propranolol can help them cope with alcohol cravings effectively.
2. A client in the operating room received a dose of Succinylcholine, leading to muscle rigidity and a sudden rise in body temperature. The nurse should anticipate a prescription for which of the following medications?
- A. Neostigmine
- B. Naloxone
- C. Dantrolene
- D. Vecuronium
Correct answer: C
Rationale: Muscle rigidity and a sudden rise in temperature are indicative of malignant hyperthermia, a potential complication of succinylcholine. Dantrolene is the drug of choice to treat malignant hyperthermia as it acts on skeletal muscles to reduce metabolic activity and counteract the symptoms. Neostigmine (Choice A) is used to reverse the effects of non-depolarizing neuromuscular blocking agents, not for malignant hyperthermia. Naloxone (Choice B) is an opioid antagonist used for opioid overdose. Vecuronium (Choice D) is a non-depolarizing neuromuscular blocking agent and is not the appropriate medication for malignant hyperthermia.
3. A client has been prescribed Valsartan. Which of the following adverse effects should the nurse monitor?
- A. Hyperkalemia
- B. Hypoglycemia
- C. Bradycardia
- D. Hypercalcemia
Correct answer: A
Rationale: Corrected Rationale: Valsartan is an angiotensin II receptor blocker (ARB) that can lead to hyperkalemia by inhibiting the action of aldosterone. Hyperkalemia is a potential adverse effect, making it essential for the nurse to closely monitor the client's potassium levels to prevent complications such as cardiac arrhythmias. Incorrect Options Rationale: - Option B, Hypoglycemia, is not a common adverse effect of Valsartan. - Option C, Bradycardia, is not typically associated with Valsartan use. - Option D, Hypercalcemia, is not a known adverse effect of Valsartan; instead, Valsartan can lead to hyperkalemia.
4. A provider prescribes phenobarbital for a client who has a seizure disorder. The medication has a long half-life of 4 days. How many times per day should the nurse expect to administer this medication?
- A. One
- B. Two
- C. Three
- D. Four
Correct answer: A
Rationale: Phenobarbital, with a long half-life of 4 days, remains at therapeutic levels in the body for an extended period. Due to this prolonged duration of action, the nurse should administer phenobarbital once a day to maintain a consistent therapeutic effect without the need for multiple daily doses. Administering the medication more than once a day would not be necessary and could increase the risk of side effects or toxicity. Therefore, the correct answer is to administer phenobarbital once a day.
5. A client has a new prescription for a Fentanyl transdermal patch. Which of the following instructions should the nurse include?
- A. Apply the patch to a non-hairy area.
- B. Change the patch every 72 hours.
- C. Avoid exposure to heat sources.
- D. Do not cut the patch to adjust the dosage.
Correct answer: C
Rationale: The correct instruction the nurse should include for a client using a Fentanyl transdermal patch is to avoid exposure to heat sources. Heat can increase the absorption of the medication, potentially causing an overdose. Instructing the client to avoid heat sources is crucial to ensure their safety and the effectiveness of the medication. Choices A, B, and D are incorrect because applying the patch to a non-hairy area, changing it every 72 hours, and not cutting the patch are general guidelines for using transdermal patches but do not specifically address the unique risks associated with Fentanyl patches.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 50,000 Questions with answers
- All ATI courses Coverage
- 30 days access @ $69.99
ATI RN Premium
$149.99/ 90 days
- 50,000 Questions with answers
- All ATI courses Coverage
- 30 days access @ $149.99